Pharmacokinetics of olanzapine in Chinese male schizophrenic patients with various smoking behaviors

Tzu Hua Wu, Chih Chiang Chiu, Winston W. Shen, Fang Wei Lin, Li Hsuan Wang, Hsiang Yu Chen, Mong Liang Lu

Research output: Contribution to journalArticle

22 Citations (Scopus)

Abstract

Tobacco consumption has been recognized as a factor mediating the interindividual variations in olanzapine's pharmacokinetics and pharmacodynamics. The primary objective of this study was to describe the dose effect of smoking on the dose-plasma concentration relationship and the pharmacokinetics of oral olanzapine in male schizophrenic patients using high-performance liquid chromatography coupled with electrochemical detector. Twenty-seven male schizophrenic inpatients were recruited and were stratified into the following groups according to smoking behaviors: non-smokers (n = 9), light-smokers (1-4 cigarettes per day; n = 9), and heavy-smokers (≥ 5 cigarettes per day; n = 9). Plasma olanzapine concentrations were determined up to 120 h following a single oral dose of 10 mg olanzapine. The pharmacokinetic parameters were calculated by the non-compartment method using WinNonlin software. Results show that there was a significant correlation among non-smokers (n = 9; 0.79; p = 0.01) or combined with light-smokers (n = 18; 0.62; p <0.01) between peak plasma olanzapine concentrations (Cmax) and their individual dose-corrected by body weight, but this correlation did not appear in heavy-smokers. There were no significant differences between non-smokers and light-smokers except for significant decreased AUC0→120 by 45.1% in light-smokers. The mean Cmax and the mean area under the plasma concentration-time curve from time zero to 120 h (AUC0→120) of the heavy-smoking patients was 9.3 ± 4.3 ng/ml (65.2% reduction compared to the non-smokers) and 302.4 ± 167.8 h ng/ml (67.6% reduction compared to the non-smokers), respectively. In summary, a daily consumption of 5 cigarettes is probably sufficient for induction of olanzapine metabolism. Smoking cessation is recommended for olanzapine therapy to have better prediction for therapeutic dosages particularly in heavy-smokers. Compared to non-smokers, heavy-smokers therefore require a 50-100% increase in olanzapine doses. Therapeutic drug monitoring will need to be considered when schizophrenic patients change their smoking behaviors.

Original languageEnglish
Pages (from-to)1889-1893
Number of pages5
JournalProgress in Neuro-Psychopharmacology and Biological Psychiatry
Volume32
Issue number8
DOIs
Publication statusPublished - Dec 12 2008

Fingerprint

olanzapine
Pharmacokinetics
Smoking
Tobacco Products
Light
Drug Monitoring
Tobacco Use
Smoking Cessation
Inpatients

Keywords

  • Dose-concentration relationship
  • Olanzapine
  • Pharmacokinetics
  • Schizophrenia
  • Smoking behavior

ASJC Scopus subject areas

  • Biological Psychiatry
  • Pharmacology

Cite this

Pharmacokinetics of olanzapine in Chinese male schizophrenic patients with various smoking behaviors. / Wu, Tzu Hua; Chiu, Chih Chiang; Shen, Winston W.; Lin, Fang Wei; Wang, Li Hsuan; Chen, Hsiang Yu; Lu, Mong Liang.

In: Progress in Neuro-Psychopharmacology and Biological Psychiatry, Vol. 32, No. 8, 12.12.2008, p. 1889-1893.

Research output: Contribution to journalArticle

@article{2615c7489a1849a4b5ec16cd0b44fbed,
title = "Pharmacokinetics of olanzapine in Chinese male schizophrenic patients with various smoking behaviors",
abstract = "Tobacco consumption has been recognized as a factor mediating the interindividual variations in olanzapine's pharmacokinetics and pharmacodynamics. The primary objective of this study was to describe the dose effect of smoking on the dose-plasma concentration relationship and the pharmacokinetics of oral olanzapine in male schizophrenic patients using high-performance liquid chromatography coupled with electrochemical detector. Twenty-seven male schizophrenic inpatients were recruited and were stratified into the following groups according to smoking behaviors: non-smokers (n = 9), light-smokers (1-4 cigarettes per day; n = 9), and heavy-smokers (≥ 5 cigarettes per day; n = 9). Plasma olanzapine concentrations were determined up to 120 h following a single oral dose of 10 mg olanzapine. The pharmacokinetic parameters were calculated by the non-compartment method using WinNonlin software. Results show that there was a significant correlation among non-smokers (n = 9; 0.79; p = 0.01) or combined with light-smokers (n = 18; 0.62; p <0.01) between peak plasma olanzapine concentrations (Cmax) and their individual dose-corrected by body weight, but this correlation did not appear in heavy-smokers. There were no significant differences between non-smokers and light-smokers except for significant decreased AUC0→120 by 45.1{\%} in light-smokers. The mean Cmax and the mean area under the plasma concentration-time curve from time zero to 120 h (AUC0→120) of the heavy-smoking patients was 9.3 ± 4.3 ng/ml (65.2{\%} reduction compared to the non-smokers) and 302.4 ± 167.8 h ng/ml (67.6{\%} reduction compared to the non-smokers), respectively. In summary, a daily consumption of 5 cigarettes is probably sufficient for induction of olanzapine metabolism. Smoking cessation is recommended for olanzapine therapy to have better prediction for therapeutic dosages particularly in heavy-smokers. Compared to non-smokers, heavy-smokers therefore require a 50-100{\%} increase in olanzapine doses. Therapeutic drug monitoring will need to be considered when schizophrenic patients change their smoking behaviors.",
keywords = "Dose-concentration relationship, Olanzapine, Pharmacokinetics, Schizophrenia, Smoking behavior",
author = "Wu, {Tzu Hua} and Chiu, {Chih Chiang} and Shen, {Winston W.} and Lin, {Fang Wei} and Wang, {Li Hsuan} and Chen, {Hsiang Yu} and Lu, {Mong Liang}",
year = "2008",
month = "12",
day = "12",
doi = "10.1016/j.pnpbp.2008.08.022",
language = "English",
volume = "32",
pages = "1889--1893",
journal = "Progress in Neuro-Psychopharmacology and Biological Psychiatry",
issn = "0278-5846",
publisher = "Elsevier Inc.",
number = "8",

}

TY - JOUR

T1 - Pharmacokinetics of olanzapine in Chinese male schizophrenic patients with various smoking behaviors

AU - Wu, Tzu Hua

AU - Chiu, Chih Chiang

AU - Shen, Winston W.

AU - Lin, Fang Wei

AU - Wang, Li Hsuan

AU - Chen, Hsiang Yu

AU - Lu, Mong Liang

PY - 2008/12/12

Y1 - 2008/12/12

N2 - Tobacco consumption has been recognized as a factor mediating the interindividual variations in olanzapine's pharmacokinetics and pharmacodynamics. The primary objective of this study was to describe the dose effect of smoking on the dose-plasma concentration relationship and the pharmacokinetics of oral olanzapine in male schizophrenic patients using high-performance liquid chromatography coupled with electrochemical detector. Twenty-seven male schizophrenic inpatients were recruited and were stratified into the following groups according to smoking behaviors: non-smokers (n = 9), light-smokers (1-4 cigarettes per day; n = 9), and heavy-smokers (≥ 5 cigarettes per day; n = 9). Plasma olanzapine concentrations were determined up to 120 h following a single oral dose of 10 mg olanzapine. The pharmacokinetic parameters were calculated by the non-compartment method using WinNonlin software. Results show that there was a significant correlation among non-smokers (n = 9; 0.79; p = 0.01) or combined with light-smokers (n = 18; 0.62; p <0.01) between peak plasma olanzapine concentrations (Cmax) and their individual dose-corrected by body weight, but this correlation did not appear in heavy-smokers. There were no significant differences between non-smokers and light-smokers except for significant decreased AUC0→120 by 45.1% in light-smokers. The mean Cmax and the mean area under the plasma concentration-time curve from time zero to 120 h (AUC0→120) of the heavy-smoking patients was 9.3 ± 4.3 ng/ml (65.2% reduction compared to the non-smokers) and 302.4 ± 167.8 h ng/ml (67.6% reduction compared to the non-smokers), respectively. In summary, a daily consumption of 5 cigarettes is probably sufficient for induction of olanzapine metabolism. Smoking cessation is recommended for olanzapine therapy to have better prediction for therapeutic dosages particularly in heavy-smokers. Compared to non-smokers, heavy-smokers therefore require a 50-100% increase in olanzapine doses. Therapeutic drug monitoring will need to be considered when schizophrenic patients change their smoking behaviors.

AB - Tobacco consumption has been recognized as a factor mediating the interindividual variations in olanzapine's pharmacokinetics and pharmacodynamics. The primary objective of this study was to describe the dose effect of smoking on the dose-plasma concentration relationship and the pharmacokinetics of oral olanzapine in male schizophrenic patients using high-performance liquid chromatography coupled with electrochemical detector. Twenty-seven male schizophrenic inpatients were recruited and were stratified into the following groups according to smoking behaviors: non-smokers (n = 9), light-smokers (1-4 cigarettes per day; n = 9), and heavy-smokers (≥ 5 cigarettes per day; n = 9). Plasma olanzapine concentrations were determined up to 120 h following a single oral dose of 10 mg olanzapine. The pharmacokinetic parameters were calculated by the non-compartment method using WinNonlin software. Results show that there was a significant correlation among non-smokers (n = 9; 0.79; p = 0.01) or combined with light-smokers (n = 18; 0.62; p <0.01) between peak plasma olanzapine concentrations (Cmax) and their individual dose-corrected by body weight, but this correlation did not appear in heavy-smokers. There were no significant differences between non-smokers and light-smokers except for significant decreased AUC0→120 by 45.1% in light-smokers. The mean Cmax and the mean area under the plasma concentration-time curve from time zero to 120 h (AUC0→120) of the heavy-smoking patients was 9.3 ± 4.3 ng/ml (65.2% reduction compared to the non-smokers) and 302.4 ± 167.8 h ng/ml (67.6% reduction compared to the non-smokers), respectively. In summary, a daily consumption of 5 cigarettes is probably sufficient for induction of olanzapine metabolism. Smoking cessation is recommended for olanzapine therapy to have better prediction for therapeutic dosages particularly in heavy-smokers. Compared to non-smokers, heavy-smokers therefore require a 50-100% increase in olanzapine doses. Therapeutic drug monitoring will need to be considered when schizophrenic patients change their smoking behaviors.

KW - Dose-concentration relationship

KW - Olanzapine

KW - Pharmacokinetics

KW - Schizophrenia

KW - Smoking behavior

UR - http://www.scopus.com/inward/record.url?scp=56449125381&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=56449125381&partnerID=8YFLogxK

U2 - 10.1016/j.pnpbp.2008.08.022

DO - 10.1016/j.pnpbp.2008.08.022

M3 - Article

VL - 32

SP - 1889

EP - 1893

JO - Progress in Neuro-Psychopharmacology and Biological Psychiatry

JF - Progress in Neuro-Psychopharmacology and Biological Psychiatry

SN - 0278-5846

IS - 8

ER -